-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

722.O3.6 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Studies Exploring the Immunobiology of HCT

Symposia: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, AML, Fundamental Science, clinical trials, adult, Translational Research, Clinical Research, GVHD, pediatric, Diseases, Immune Disorders, immune mechanism, Therapies, immunology, Immunotherapy, real-world evidence, Adverse Events, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Study Population, Human, pathogenesis
Saturday, December 10, 2022: 9:30 AM-11:00 AM
252-254 (Ernest N. Morial Convention Center)
Moderators:
Susan DeWolf, MD, Memorial Sloan Kettering Cancer Center and Kate A Markey, MBBS, PhD, FRACP, MPH, ARRAY(0xe597a00)
Disclosures:
Markey: Incyte: Consultancy; Postbiotics Plus: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.
This session will highlight interesting new data from groups exploring T cell recovery after transplantation and include presentations of clinical data which may offer new mechanistic insights.
9:30 AM

Alexandre Albanese1*, Edward Chen, MS2*, Jillian Zavistaski1*, Kayla Betz2*, Yvonne Suessmuth, PhD3*, Lorenzo Cagnin, PhD1*, Paula Keskula1*, Kyle Kimler4*, James Kaminski1,4*, Bruce R. Blazar, MD5, Benjamin Watkins, MD6 and Leslie S. Kean, MD, PhD2

1Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston
2Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
3Emory University, Children’s Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, GA
4Broad Institute of MIT and Harvard, Cambridge
5University of Minnesota, Minneapolis, MN
6Aflac Cancer and Blood Disorders Center, Atlanta, GA

9:45 AM

Lu Cui1*, Cristabelle De Souza, Ph.D.1*, Tristan Lerbs1*, Jessica Poyser1*, Clarissa Yu2*, Kerri Rieger, MD PhD3*, Sally Arai, MD4, Ryanne Brown5*, Judith A Shizuru, MD, PhD6, Antonia Maria Susanne Müller7* and Gerlinde Wernig, MD8

1Stanford University, Stanford, CA
2Stanford University, Stanford
3Stanford University, Palo Alto, CA
4Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University Medical Center, Stanford, CA
5Stanford, Stanford, CA
6Division of BMT and Cellular Therapy, Stanford University, Stanford, CA
7Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
8Stanford Hospital & Clinics, Stanford, CA

10:00 AM

Alexandre Albanese1*, Alal Eran, PhD2*, Yvonne Suessmuth, PhD3*, Kayla Betz, BS, MPH4*, Brandi Bratrude5*, Paula Keskula6*, Lorenzo Cagnin, PhD4*, Amelia Langston, MD7, Muna Qayed, MD, MSc8, John T. Horan, MD, MPH9, Bruce R. Blazar, MD10, Benjamin Watkins, MD3 and Leslie S. Kean, MD, PhD11

1Department of Hematology and Oncology, Boston Children's Hospital, Boston, MA
2Boston Children's Hospital, Boston
3Emory University, Children’s Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, GA
4Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston
5Dana-Farber Cancer Institute, Boston Children's Hospital, Boston
6Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
7Emory University, Winship Cancer Institute, Atlanta, GA
8Emory University, Atlanta, GA
9Dana-Farber Cancer Institute, Boston Children’s Hospital, Boston, MA
10University of Minnesota, Minneapolis, MN
11Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA

10:15 AM

Florent Malard, MD, PhD1*, Michael Loschi, MD, PhD2*, Thomas Cluzeau, MD, PhD3, Faezeh Legrand, MD4*, Jean-Baptiste Mear, MD, PhD5*, Faustine Lhomme, MD, PhD6*, Sarah Guenounou, MD7*, Anne Huynh8*, Cecile Borel, MD9*, Deborah Desmier, MD10*, Niels Moya, MD11*, Amandine Charbonnier, MD12*, Delphine Lebon, MD12*, Hélène Labussière-Wallet13*, Corentin Orvain, MD, PhD14*, Sylvain Chantepie, MD15*, Claude-Eric Bulabois, MD16*, Vincent Camus, MD17*, Marie-Anne Couturier, MD18*, Jérôme Cornillon, MD19*, Patrice Chevallier, MD20, Clémence Mediavilla21*, Patrice Ceballos, MD, PhD22*, David Beauvais, MD23*, Marion Bruelle, PharmD, PhD24*, Emilie Plantamura, PhD, PharmD24* and Mohamad Mohty, MD PhD25

1Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint Antoine Hospital, Assistance Publique - Hôpitaux de Paris, INSERM UMRs 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
2Hematology department, CHU de Nice, Universite Cote d'Azur, Nice, France
3Département d'Hématologie Clinique, Université Côte d'Azur, CHU Nice, Nice, Provence Alpes Cote d'Azur, France
4Hematology Department, Institut Paoli-Calmettes, Marseille, France
5Clinical hematology, University Hospital of Rennes, Rennes, France
6Hematology department, CHU of Rennes, Rennes, France
7Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
8Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
9Hematology Department, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
10CHU de Poitiers, Service d'Hématologie et de thérapie cellulaire, Poitiers, France
11Hematology and cellular therapy department, CHU Poitiers, POITIERS, France
12Service d’Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d’Amiens, Amiens, France
13Clinical hematology service, Hospices Civils de Lyon, Lyon, France
14Angers University Hospital, Angers, France
15Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen Cedex 9, France
16Service d'Hématologie, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
17Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France
18Brest University Hospital, Brest, France
19Hematology department, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France
20Hematology Department, Nantes University Hospital, Nantes, France
21Saint-Antoine Hospital, AP-HP, Paris, FRA
22Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
23Department of Hematology, University Hospital of Lille, Lille, France
24MaaT Pharma, Lyon, France
25EBMT Paris study office / CEREST-TC, Paris, France, Department of Hematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Sorbonne University, Paris, France

10:30 AM

Caden Ulschmid1*, Xiao Li, MS2*, Tao Wang, PhD1,2*, Brent Logan, PhD1,2*, Joseph Pidala, MD, PhD3, Margaret L. MacMillan, MD4, Carrie Lynn Kitko, MD5, Stephanie J. Lee, MD, MPH1,6*, Stephen R. Spellman7* and Wael Saber, MD, MS1

1CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
2Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
3Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
4Blood and Marrow Transplant Program, Department of Pediatrics, University Of Minnesota, Minneapolis, MN
5Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN
6Fred Hutchinson Cancer Research Center, Seattle
7CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN

10:45 AM

Alex Hoover, MD1, Daniel O'Leary, MD2, Qing Cao, MS3*, Ashish O. Gupta, MBBS, MPH4, Christen L. Ebens, MD, MPH4, Joseph E. Maakaron, MD2, Brian C. Betts, MD2, Mark Juckett, MD5, Troy C. Lund, MD, PhD, MS4, Veronika Bachanova, MD, PhD2, Margaret L. MacMillan, MD4, Jeffrey S. Miller, MD, MD2, Paul J. Orchard, MD4*, John E Wagner, MD4, Gregory M. Vercellotti, MD2, Daniel J. Weisdorf, MD6, Kathryn Dusenbery, MD7*, Stephanie Terezakis, MD7*, Shernan G Holtan, MD8 and Najla H El Jurdi, MD2

1Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN
2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
3Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
4Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN
5Masonic Cancer Center, University of Minnesota, Minneapolis, MN
6Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
7Department of Radiation Oncology, University of Minnesota, Minneapolis, MN
8University of Minnesota, Minneapolis, MN

*signifies non-member of ASH